PE20190732A1 - Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje - Google Patents
Compuestos y composiciones como inhibidores de los receptores endosomales tipo peajeInfo
- Publication number
- PE20190732A1 PE20190732A1 PE2019000478A PE2019000478A PE20190732A1 PE 20190732 A1 PE20190732 A1 PE 20190732A1 PE 2019000478 A PE2019000478 A PE 2019000478A PE 2019000478 A PE2019000478 A PE 2019000478A PE 20190732 A1 PE20190732 A1 PE 20190732A1
- Authority
- PE
- Peru
- Prior art keywords
- type
- methyl
- pyrazolo
- pyridin
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- ZWVCZRQPYARBEI-UHFFFAOYSA-N 4-[[3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CC1=NN(C2=C1CN(CC2)C1=C2C(=NC(=C1)C)NN=C2)CC12CCC(CC1)(CC2)N ZWVCZRQPYARBEI-UHFFFAOYSA-N 0.000 abstract 1
- XGRLHCCHDAZYII-UHFFFAOYSA-N 4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]bicyclo[2.2.2]octan-1-amine Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)N)C XGRLHCCHDAZYII-UHFFFAOYSA-N 0.000 abstract 1
- RCPFKNIWFCVDLQ-UHFFFAOYSA-N 4-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1C2CCC1ONC2 RCPFKNIWFCVDLQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 abstract 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 abstract 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un compuesto que tiene la estructura de la Formula (A), o una sal farmaceuticamente aceptable del mismo; en donde L es -CH2- o -CH2CH2-; Y1 es -CH2- o -CH2CH2-; Y2 es -CH2- o -CH2CH2-; Y3 es -CH2-, -XCH2- o -CH2X-; X es -CH2- u O; R1 es -NHC(=O)R6, entre otros; R2 es H, alquiloC1-C6, haloalquilo C1-C6 o alquilo C1-C6; R6 es un cicloalquilo C3-C6, un oxa-3-azabiciclo[3.2.1] octano o una heterocicloalquilo de 4-6 miembrosque tiene 1 a 2 miembros de anillo, R17 puede ser H y alquilo C1-C6. Son compuestos preferidos 4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3- c]piridin-1-il)metil)biciclo[2,2,2]octan-1-amina; 4-((3-metil-5-(6-metil-1H-pirazolo[3,4-b]piridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciclo[2,2,2]octan-1-amina. Dichos compuestos son capaces de inhibir un receptor endosomal tipo Peaje (por ejemplo, TLR7, TLR8 o TLR9) y cualquier combinacion de los mismos y son utiles en el tratamiento de enfermedades autoinmunes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385726P | 2016-09-09 | 2016-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190732A1 true PE20190732A1 (es) | 2019-05-23 |
Family
ID=60001955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000478A PE20190732A1 (es) | 2016-09-09 | 2017-09-06 | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10954233B2 (es) |
| EP (2) | EP4059934A1 (es) |
| JP (1) | JP6779371B2 (es) |
| KR (2) | KR102411532B1 (es) |
| CN (2) | CN115215886B (es) |
| AU (1) | AU2017323584C1 (es) |
| CA (1) | CA3031585A1 (es) |
| CL (1) | CL2019000588A1 (es) |
| CO (1) | CO2019003397A2 (es) |
| CR (1) | CR20190119A (es) |
| CU (1) | CU24526B1 (es) |
| CY (1) | CY1125007T1 (es) |
| DK (1) | DK3510033T3 (es) |
| DO (1) | DOP2019000055A (es) |
| EA (1) | EA036880B1 (es) |
| EC (1) | ECSP19024046A (es) |
| ES (1) | ES2905981T3 (es) |
| HR (1) | HRP20220144T1 (es) |
| HU (1) | HUE057254T2 (es) |
| IL (1) | IL265159B (es) |
| JO (1) | JOP20190041B1 (es) |
| LT (1) | LT3510033T (es) |
| MA (1) | MA46196A (es) |
| MX (1) | MX382383B (es) |
| MY (1) | MY194813A (es) |
| NZ (1) | NZ750781A (es) |
| PE (1) | PE20190732A1 (es) |
| PH (1) | PH12019500161A1 (es) |
| PL (1) | PL3510033T3 (es) |
| PT (1) | PT3510033T (es) |
| RS (1) | RS62913B1 (es) |
| RU (1) | RU2759678C2 (es) |
| SG (1) | SG11201900482SA (es) |
| SI (1) | SI3510033T1 (es) |
| WO (1) | WO2018047081A1 (es) |
| ZA (1) | ZA201900227B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3929196T1 (sl) | 2013-09-24 | 2023-11-30 | Fujifilm Corporation | Farmacevtska sestava spojine, ki vsebuje dušik ali njegovo sol ali njegov kovinski kompleks |
| ES2990113T3 (es) | 2016-07-07 | 2024-11-28 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Conjugados de adyuvantes de anticuerpos |
| WO2018047081A1 (en) | 2016-09-09 | 2018-03-15 | Novartis Ag | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| WO2018071849A2 (en) | 2016-10-14 | 2018-04-19 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| WO2019123294A2 (en) | 2017-12-22 | 2019-06-27 | Novartis Ag | Novel uses of pyrazolo piperidine derivatives |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| IL318069A (en) | 2018-03-30 | 2025-02-01 | Incyte Corp | Using JAK inhibitors to treat hidradenitis suppurativa |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| TWI826446B (zh) * | 2018-05-18 | 2023-12-21 | 瑞士商諾華公司 | Tlr7/tlr8抑制劑之晶型 |
| WO2019233941A1 (en) | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| JP7434186B2 (ja) | 2018-06-12 | 2024-02-20 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物 |
| JP7366994B2 (ja) | 2018-07-23 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11639352B2 (en) | 2018-09-04 | 2023-05-02 | Hoffman-La Roche Inc. | Benzothiazole compounds for the treatment of autoimmune diseases |
| WO2020048595A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| US20210253575A1 (en) * | 2018-09-07 | 2021-08-19 | Hoffmann-La Roche Inc. | Pyrrolidine amine compounds for the treatment of autoimmune disease |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR102808642B1 (ko) | 2019-03-07 | 2025-05-14 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020240272A1 (en) * | 2019-05-31 | 2020-12-03 | Dr.Reddy's Institute Of Life Sciences | Preparation of novel 1 h-pyrazolo[4,3-d]pyrimidines, their compositions, synthesis and methods of using them for treating tuberculosis |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20250040096A (ko) | 2019-09-30 | 2025-03-21 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| CN114599652B (zh) | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| JP7649306B2 (ja) | 2019-11-20 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物 |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021154662A1 (en) * | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN115835910A (zh) * | 2020-07-14 | 2023-03-21 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢化异喹啉或氢化萘啶化合物 |
| KR102513463B1 (ko) * | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| WO2022221642A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7654118B2 (ja) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202440078A (zh) | 2021-09-10 | 2024-10-16 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| CN118076604A (zh) | 2021-09-24 | 2024-05-24 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡唑并[3,4-b]吡啶化合物 |
| US20250090538A1 (en) | 2022-01-11 | 2025-03-20 | Novartis Ag | Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0113176A (pt) | 2000-08-10 | 2003-06-17 | Pharmacia Italia Spa | Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP2006519816A (ja) | 2003-03-11 | 2006-08-31 | ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ | キナーゼ阻害剤として活性なビシクロピラゾール誘導体、それらの製造方法、及びそれらを含んでなる医薬組成物 |
| KR20070074638A (ko) | 2004-10-27 | 2007-07-12 | 얀센 파마슈티카 엔.브이. | 테트라하이드로 피리디닐 피라졸 카나비노이드 모듈레이터 |
| US20070093515A1 (en) * | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| WO2007034817A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| US20070254913A1 (en) | 2006-04-19 | 2007-11-01 | Dunn Robert F | Phosphodiesterase 4 inhibitors |
| PE20090213A1 (es) | 2007-05-04 | 2009-02-28 | Bristol Myers Squibb Co | Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos |
| ES2389992T3 (es) * | 2007-11-02 | 2012-11-05 | Vertex Pharmaceuticals Incorporated | Derivados de [1H-pirazolo[3,4-b]piridin-4-il]-fenilo o -piridin-2-ilo como proteína cinasa c-theta |
| BR112012003703A2 (pt) * | 2009-08-18 | 2020-12-08 | Ventrix Phramaceuticals, INC. | Benzoazepinas substituídas como moduladores do receptor tipo toll |
| WO2011049825A1 (en) * | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012154608A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive mtor and pi3 kinase inhibitors and uses thereof |
| US20140243302A1 (en) | 2011-06-27 | 2014-08-28 | Merck Sharp & Dohme Corporation | Bridged bicyclic compounds for the treatment of bacterial infections |
| ES2716811T3 (es) * | 2012-02-08 | 2019-06-17 | Janssen Sciences Ireland Unlimited Co | Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| JPWO2014034719A1 (ja) | 2012-08-29 | 2016-08-08 | 興和株式会社 | Ｔｌｒ阻害作用を有するキノリン誘導体 |
| AU2013328732B2 (en) | 2012-10-10 | 2017-08-31 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
| EP2945938B1 (en) | 2013-01-18 | 2018-03-07 | F. Hoffmann-La Roche AG | 3-substituted pyrazoles and use as dlk inhibitors |
| JP2016516708A (ja) | 2013-03-14 | 2016-06-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ビシクロ［２．２．２］酸のｇｐｒ１２０モジュレーター |
| GEP201706675B (en) | 2013-05-02 | 2017-05-25 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
| US10471139B2 (en) * | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| US10189786B2 (en) | 2013-08-16 | 2019-01-29 | Duke University | Antibacterial compounds |
| EP3036102A4 (en) | 2013-08-19 | 2017-01-25 | Queen's University At Kingston | Carbene functionalized composite materials |
| US20160096850A9 (en) | 2013-08-22 | 2016-04-07 | Genentech, Inc. | Alkynyl alcohols and methods of use |
| WO2015036044A1 (en) | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
| JP6223563B2 (ja) * | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| MX363708B (es) | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
| WO2016004272A1 (en) * | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US9962388B2 (en) | 2014-08-15 | 2018-05-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| WO2016097918A1 (en) * | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
| JP6713465B2 (ja) | 2014-12-30 | 2020-06-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎感染症治療のための誘導体及び方法 |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| EP3268356B1 (en) | 2015-03-12 | 2021-08-25 | Novartis Ag | Heterocyclic compounds and methods for their use |
| FI3429591T3 (fi) | 2016-03-16 | 2023-06-15 | Kura Oncology Inc | Substituoituja tieno[2,3-d]pyrimidiinijohdannaisia meniini-mll:n estäjinä ja käyttömenetelmiä |
| WO2018047081A1 (en) | 2016-09-09 | 2018-03-15 | Novartis Ag | Compounds and compositions as inhibitors of endosomal toll-like receptors |
-
2017
- 2017-09-06 WO PCT/IB2017/055375 patent/WO2018047081A1/en not_active Ceased
- 2017-09-06 EP EP21208454.5A patent/EP4059934A1/en active Pending
- 2017-09-06 PE PE2019000478A patent/PE20190732A1/es unknown
- 2017-09-06 HU HUE17777966A patent/HUE057254T2/hu unknown
- 2017-09-06 JP JP2019513008A patent/JP6779371B2/ja active Active
- 2017-09-06 CN CN202210863391.4A patent/CN115215886B/zh active Active
- 2017-09-06 CR CR20190119A patent/CR20190119A/es unknown
- 2017-09-06 MX MX2019002797A patent/MX382383B/es unknown
- 2017-09-06 KR KR1020217018684A patent/KR102411532B1/ko active Active
- 2017-09-06 PL PL17777966T patent/PL3510033T3/pl unknown
- 2017-09-06 LT LTEPPCT/IB2017/055375T patent/LT3510033T/lt unknown
- 2017-09-06 MY MYPI2019000071A patent/MY194813A/en unknown
- 2017-09-06 JO JOP/2019/0041A patent/JOP20190041B1/ar active
- 2017-09-06 AU AU2017323584A patent/AU2017323584C1/en active Active
- 2017-09-06 RU RU2019110157A patent/RU2759678C2/ru active
- 2017-09-06 PT PT177779667T patent/PT3510033T/pt unknown
- 2017-09-06 CN CN201780053304.6A patent/CN109641899B/zh active Active
- 2017-09-06 MA MA046196A patent/MA46196A/fr unknown
- 2017-09-06 SG SG11201900482SA patent/SG11201900482SA/en unknown
- 2017-09-06 DK DK17777966.7T patent/DK3510033T3/da active
- 2017-09-06 NZ NZ750781A patent/NZ750781A/en unknown
- 2017-09-06 HR HRP20220144TT patent/HRP20220144T1/hr unknown
- 2017-09-06 ES ES17777966T patent/ES2905981T3/es active Active
- 2017-09-06 RS RS20220087A patent/RS62913B1/sr unknown
- 2017-09-06 EP EP17777966.7A patent/EP3510033B1/en active Active
- 2017-09-06 US US16/330,820 patent/US10954233B2/en active Active
- 2017-09-06 SI SI201731065T patent/SI3510033T1/sl unknown
- 2017-09-06 EA EA201990657A patent/EA036880B1/ru not_active IP Right Cessation
- 2017-09-06 KR KR1020197008484A patent/KR20190039809A/ko not_active Withdrawn
- 2017-09-06 CU CU2019000018A patent/CU24526B1/es unknown
- 2017-09-06 CA CA3031585A patent/CA3031585A1/en active Pending
-
2019
- 2019-01-14 ZA ZA201900227A patent/ZA201900227B/en unknown
- 2019-01-22 PH PH12019500161A patent/PH12019500161A1/en unknown
- 2019-03-04 IL IL265159A patent/IL265159B/en unknown
- 2019-03-06 DO DO2019000055A patent/DOP2019000055A/es unknown
- 2019-03-08 CL CL2019000588A patent/CL2019000588A1/es unknown
- 2019-04-05 EC ECSENADI201924046A patent/ECSP19024046A/es unknown
- 2019-04-05 CO CONC2019/0003397A patent/CO2019003397A2/es unknown
-
2020
- 2020-12-16 US US17/124,346 patent/US20210101902A1/en not_active Abandoned
-
2022
- 2022-02-22 CY CY20221100153T patent/CY1125007T1/el unknown
-
2024
- 2024-05-30 US US18/678,198 patent/US20240376099A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190732A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
| CR20190149A (es) | Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1 | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| UY35935A (es) | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| AR094550A1 (es) | Inhibidores de btk |